Navigation Links
VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
Date:9/9/2009

MOUNTAIN VIEW, Calif., Sept. 9 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes.

Key Data

Highlights from the EQUIP and CONQUER studies include:

  • Average weight loss of 14.7% (37 lbs) was achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
  • Significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
  • FDA efficacy benchmarks for weight loss agents exceeded at all three doses of Qnexa tested in the clinical program;
  • Completion rates up to 69% were significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability; and
  • Favorable benefit/risk safety profile for Qnexa.

"The outstanding results from the EQUIP and CONQUER studies, in addition to the results from EQUATE that were reported late last year, confirm the positive effect of Qnexa and underscore the important role this therapy may play in the lives of patients battling obesity and related co-morbidities, if approved by the FDA," stated Leland Wilson, president and chief executive offic
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. VIVUS to Present at Four Upcoming Healthcare Conferences
2. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
5. VIVUS Reports First Quarter 2009 Financial Results and Highlights
6. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
7. Verenium Announces Reverse Stock Split to Take Effect September 9
8. BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale
9. American Oriental Bioengineering Announces September Investor Conferences Participation
10. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
11. Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 BioPlus ... leading specialty pharmacies, has an expanded team of ... pharmacy consultants for prescriber offices in their regions, ... , “We have a variety of Regional Pharmaceutical ... those specializing in hepatitis C help prescribers understand ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that ... Board, to succeed Donald Fresne ; Mr. Fresne has ... a member of the Board.  In recognition of the many ... over almost twenty years, the Board designated Mr. Fresne as ... established a Search Committee to find a suitable replacement with ...
(Date:12/17/2014)... 2014 “Never say, ‘I cannot ... Marburg’s Department of Physics, advises young women pursuing ... released SPIE Women in Optics 18-month planner ... to ask questions.” , In the annual planner, ... occupations ranging from university professor and laboratory researcher ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... and SEATTLE, Jan. 5, 2012 CMC Biologics, ... issuance of European Patent No. US 2,171,034 B1 ... fermentations and mammalian cell culture bioreactors. The invention ... in a continuous perfusion fermentation process, wherein the ...
... Technologies Corporation (NASDAQ: LIFE ) has ... de Normalisation (AFNOR) for its MicroSEQ® Listeria ... assays, molecular tests that are designed to ... this food-borne pathogen that most recently has been associated ...
... SYDNEY, Jan. 4, 2012 The Company today announced that ... ("ADR") program.  The previous conversion ratio of 5 Novogen Limited ... Novogen Limited ordinary shares for each ADR share.  The change ... the ADR ratio will have no effect on the number ...
Cached Biology Technology:CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems 2Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 2Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 3Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples 4
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Hippocampus adapts to environmental stresses, Stockpiles ... under favorable conditions, Knowledge of how neural stem cells ... diseases such as Alzheimer,s and Parkinson,s ... known for years that neurogenesis takes place throughout adulthood ...
... German . , The brains of all vertebrates ... the brain areas that control their singing behaviour could be ... songbird species, only the males sing and indeed, they do ... However, even species where both sexes sing identically, display the ...
... It sounds like something out of a comic book ... but that is exactly what two investigators at the Wellman ... In a report that will appear in the journal ... researchers Malte Gather, PhD, and Seok Hyun Yun, PhD, describe ...
Cached Biology News:Brain structure adapts to environmental change 2Birdsong independent of brain size 2Birdsong independent of brain size 3Single GFP-expressing cell is basis of living laser device 2Single GFP-expressing cell is basis of living laser device 3
...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Human PDGF, CF...
... ultimate in utility and flexibility press-to-seal silicone ... needs of the researcher. They are available ... as sheet material that can be easily ... are autoclavable and non-cytotoxic and can be ...
Biology Products: